ESMO-MCBS v1.1 评估颅外寡转移 NSCLC 立体定向放疗的临床获益
本研究将 ESMO 临床获益量表 v1.1 应用于 ASTRO/ESTRO 指南所依据的 23 项研究及 2 项近期试验,共 25 项。结果显示,立体定向体部放疗联合标准化疗用于全部寡转移灶可带来生存获益,评分达 4 分;10 项前瞻性单臂研究中 9 项因无进展生存超过 6 个月评 3 分,无研究获最高 5 分。
要点
- 立体定向放疗联合标准化疗用于全部寡转移灶与生存显著改善相关,ESMO-MCBS 评 4 分。
- 10 项前瞻性单臂研究中 9 项因无进展生存超过 6 个月评 3 分。
- 无研究获 5 分,若未来试验发现生活质量改善则评分可能更高。
核心结论
- 按 ESMO-MCBS v1.1,颅外寡转移 NSCLC 的局部放疗与实质性临床获益相关。
- 放疗的临床获益与帕博利珠单抗联合培美曲塞及奥希替尼等靶向治疗相当。
研究设计与样本
- 将 ESMO-MCBS v1.1 应用于 ASTRO/ESTRO 工作组识别的 23 项研究,并评估 2 项近期发表的试验,共 25 项研究。
- 所有研究由至少 3 名作者评分,分歧由评分作者复核。
主要发现
- 立体定向体部放疗联合标准化疗用于全部寡转移灶与生存显著改善相关,采用表 2a 评 4 分(标准化疗总生存 12 至 24 个月)。
- 10 项前瞻性单臂研究中 9 项采用表 3 评 3 分,原因是无进展生存超过 6 个月。
- 无研究获得最高 5 分。
关键数值与推荐
- 表 2a 评 4 分对应非治愈性治疗且标准化疗总生存 12 至 24 个月。
- 表 3 评 3 分对应前瞻性单臂研究中无进展生存超过 6 个月。
临床怎么用
- 可将 ESMO-MCBS v1.1 用于评估颅外寡转移 NSCLC 放疗研究的临床获益水平。
- 立体定向放疗联合标准化疗用于全部寡转移灶的获益评分为 4 分,可作为临床决策参考。
局限性
- 纳入评估的部分研究为前瞻性单臂研究,证据等级有限。
- 未发现生活质量改善数据,若未来试验发现生活质量改善则评分可能更高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The European Society of Medical Oncology (ESMO) magnitude of clinical benefit scale (MCBS) version 1.1 is an evaluation scale that was developed to evaluate the MCBS reported in clinical research studies of cancer treatments. The American Society for Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) created joint guidelines for the use of local therapy in the management of extracranial oligometastatic non-small cell lung cancer (NSCLC). We applied the ESMO-MCBS v.1.1 to evaluate the clinical benefit reported in studies that informed the ASTRO/ESTRO guidelines. METHODS AND MATERIALS: We applied the ESMO-MCBS v1.1 to the 23 studies identified by the ASTRO/ESTRO taskforce. As well, we evaluated the recently published Consolidative Use of Radiotherapy to Block Oligoprogression study and Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer Trial, for a total of 25 studies evaluated. All evaluated studies were graded by at least 3 of the authors. Any discrepancies were subsequently reviewed by the scoring authors. RESULTS: The addition of stereotactic body radiation therapy to all sites of oligometastatic disease in combination with standard-of-care chemotherapy was associated with substantial improvements in survival. These studies resulted in a score of 4 using form 2a (noncurative treatment with overall survival from standard therapy between 12 and 24 months). Of the 10 prospective single-arm studies, 9 received a score of 3 using form 3, due to progression-free survival exceeding 6 months. No studies received a score of 5 (highest clinical benefit). CONCLUSIONS: The use of local radiation in the treatment of extracranial oligometastatic NSCLC is associated with a substantial clinical benefit, according to the ESMO-MCBS v1.1. Radiation therapy was comparable to established and groundbreaking targeted therapies such as pembrolizumab in combination with pemetrexed for epidermal growth factor receptor and anaplastic lymphoma kinase-negative NSCLC, and osimertinib for epidermal growth factor receptor-mutated NSCLC. MCBS would be even higher if quality-of-life improvements are found in future trials.
引用
- Yu JB, Corn BW, Qureshi SS, et al. Evaluation of the European Society of Medical Oncology-Magnitude of Clinical Benefit Scale Version 1.1 for the Treatment of Extracranial Oligometastatic Non-Small Cell Lung Cancer With Radiosurgery. Pract Radiat Oncol. 2025. PMID: 40865796. doi:10.1016/j.prro.2025.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。